Actively Recruiting
Observational Study of Ravulizumab Treatment Outcomes in Polish Patients with Atypical Hemolytic Uremic Syndrome
Led by AstraZeneca · Updated on 2026-09-15
80
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This observational cohort study is designed to collect and analyze data on patients with atypical hemolytic uremic syndrome aHUS in Poland who are treated with ravulizumab as part of routine care under the National Drug Program. The study aims to track clinical outcomes and management practices over time, including patients who are new to complement inhibitor treatments and those who have switched from other therapies to ravulizumab. Participants are divided into two groups those who have never received complement inhibitors before and those who transitioned from other complement inhibitors to ravulizumab. The study involves retrospective gathering of past medical history and prospective follow-up for up to 24 months to assess treatment responses and various clinical outcomes related to aHUS and ravulizumab use. During the study, researchers will monitor patients through regular clinical evaluations, laboratory tests, and assessments of kidney function, fatigue levels, and quality of life using specific questionnaires. Key measurements include the proportion of patients achieving complete thrombotic microangiopathy TMA response, dialysis status, proteinuria changes, and functional assessments. The total follow-up period can extend to two years, allowing detailed observation of long-term treatment outcomes.
CONDITIONS
Brief Title
Ravulizumab Outcomes in Polish Patients With aHUS
Research Team
A
AstraZeneca Clinical Study Information Center Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here